News | July 31, 2009

U.K. Court Says Occlutech Did Not Infringe on AGA Patents

July 31, 2009 – A United Kingdom court has determined Occlutech GmbH’s products do not infringe on AGA Medical Holdings’ patents for atrial septal defects (ASD) and patent foramen ovale (PFO) occlusion devices.

AGA intends to appeal the decision that Occlutech did not infringe upon its patent. In January 2009, the German court of appeals in Dusseldorf enjoined Occlutech from infringing on the German part of AGA’s European patent. Occlutech is based in Jena, Germany.

“The U.K. court decision affirms the validity of AGA’s patent, while falling short of determining that Occlutech products infringe on our intellectual property, which we believe they do,” said John Barr, president and chief executive officer of AGA. “The patent at issue is only one of a number of patents that our company holds, and we will doggedly protect them against Occlutech and other companies as necessary.”

AGA Medical Holdings Inc. produces the Amplatzer occluder for structural heart defects.

For more information: www.amplatzer.com

Related Content

FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Videos | Structural Heart Occluders | June 16, 2016
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcat
PFO occluder, amplatzer
Feature | Structural Heart Occluders | May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Overlay Init